Holen Sie sich die Stockscreener-App
11.28
0.62%
0.07
Handel nachbörslich:
11.28
Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten
VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc.VERV - Business Wire
Verve Therapeutics Stock Price, Quotes and Forecasts - Benzinga
Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - MSN
Eli Lilly (LLY) Moves to Acquire Verve Therapeutics in $1B Deal - GuruFocus
Lilly to acquire Verve Therapeutics for $1.3 billion - C&EN
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Verve Therapeutics’ SWOT analysis: gene-editing stock shows promise amid challenges - Investing.com
Eli Lilly (LLY) Enters Gene-Editing Space with Verve Therapeutics Acquisition - TipRanks
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports - MSN
Verve Therapeutics downgraded to Hold from Buy at Canaccord - Yahoo Finance
Eli Lilly nears $1.3B deal for Verve Therapeuticsreport - MSN
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Beyond Obesity: Eli Lilly’s Genetic Medicine Bet On Verve Therapeutics - Forbes
This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga
HC Wainwright Downgrades Verve Therapeutics (VERV) Rating to Neutral | VERV Stock News - GuruFocus
Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus
Verve Therapeutics (VERV): Downgrade and Updated Price Target | - GuruFocus
Lilly to acquire Verve Therapeutics to advance gene editing treatments - World Pharmaceutical Frontiers
Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy - marketscreener.com
HC Wainwright Downgrades Verve Therapeutics to Neutral From Buy, $25 Price Target - MarketScreener
Verve Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Hold Rating on Verve Therapeutics Acquisition by Eli Lilly: Fair Valuation with Low Competing Bid Potential - TipRanks
Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus
Lilly Eyes Future of One-Time Cardiovascular Health with $1.3B Verve Therapeutics Acquisition - geneonline.com
Verve Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies cuts Verve Therapeutics stock rating on Lilly acquisition news - Investing.com
M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - The Globe and Mail
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B - MSN
Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover - MSN
Eli Lilly lands “bargain” deal to acquire Verve Therapeutics for $1.3bn - MSN
Why Verve Therapeutics Stock Is Skyrocketing Today - MSN
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say - The Mighty 790 KFGO
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say By Reuters - Investing.com
Lilly to acquire Verve Therapeutics for up to $1.3 billion By Investing.com - Investing.com South Africa
Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus
Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus
In a $1.3B deal, Lilly buys gene editor Verve - BioWorld MedTech
Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve - insights.citeline.com
Wilson Sonsini Advises Verve Therapeutics on IP Matters Related to Merger with Lilly - Wilson Sonsini
Stocks to Watch Recap: T-Mobile, Eli Lilly, Verve Therapeutics, First Solar - WSJ
These Stocks Moved the Most Today: Sunrun, Enphase, Verve Therapeutics, Palantir, Tesla, T-Mobile, Jabil, and More - Barron's
Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci - TipRanks
Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say - MSN
Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones - TipRanks
Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus
Eli Lilly Gets Into The Gene-Editing Space With $1 Billion Takeout - Investor's Business Daily
Verve: Eli Lilly Acquisition Based On One-Time GalNAc PCSK9 Gene Editing Program - Seeking Alpha
Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why - MSN
William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisit - GuruFocus
5 Analysts Assess Verve Therapeutics: What You Need To Know - Benzinga
Lilly to Acquire Verve Therapeutics in $1.3B Deal Targeting One-Time Gene-Editing Treatments for Cardiovascular Disease - BioPharm International
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs - upi.com
Eli Lilly lands "bargain" deal to acquire Verve Therapeutics for $1.3bn - Pharmaceutical Technology
Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum - Daily Chhattisgarh News
Eli Lilly Buys Verve Therapeutics: Aims To Permanently Lower Your Cholesterol (NYSE:LLY) - Seeking Alpha
Eli Lilly (NYSE:LLY) Eyes US$1.3 Billion Acquisition Of Verve Therapeutics - Yahoo Finance
Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion - MSN
Verve Therapeutics' Lifeline: Eli Lilly's $1.3 Billion Bet On Cardiovascular Gene Therapy (Upgrade) - Seeking Alpha
Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more - CNBC
Eli Lilly Bets Big On Gene Editing With Verve Deal - Finimize
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):